Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

s0122235

258f9ea2-0868-5f56-8e15-c34018eff445

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ESTROGEN_RESPONSE_EARLY+0.300
  • WNT_BETA_CATENIN_SIGNALING+0.300
  • APICAL_SURFACE+0.200
  • BILE_ACID_METABOLISM+0.200
  • HEME_METABOLISM+0.200
  • P53_PATHWAY+0.200
  • UV_RESPONSE_DN+0.200
  • ESTROGEN_RESPONSE_LATE+0.100
  • MITOTIC_SPINDLE+0.100
  • MYOGENESIS+0.100

Top 10 suppressed

  • MYC_TARGETS_V1-0.600
  • E2F_TARGETS-0.500
  • MYC_TARGETS_V2-0.500
  • ALLOGRAFT_REJECTION-0.400
  • G2M_CHECKPOINT-0.400
  • IL6_JAK_STAT3_SIGNALING-0.400
  • INTERFERON_GAMMA_RESPONSE-0.400
  • MTORC1_SIGNALING-0.400
  • OXIDATIVE_PHOSPHORYLATION-0.400
  • PANCREAS_BETA_CELLS-0.400

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1s0112264
melanoma-umap@29
0.903
2SRR1313116
breast-umap@18
A0.899
3ERR2208935
melanoma-umap@29
0.891
4SRR8613714
breast-umap@18
A0.888
5TCGA-BH-A0E9-01B-11R-A115-07
breast-umap@18
A0.872
6TCGA-OL-A5RV-01A-12R-A28M-07
breast-umap@18
A0.846
7TCGA-55-8097-01A-11R-2241-07
lung-landscapes@6
cohortA10.844
8SRR8613701
breast-umap@18
A0.843
9SRR6013544
lung-landscapes@6
cohortA10.836
10TCGA-D8-A4Z1-01A-21R-A266-07
breast-umap@18
A0.836

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 12 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ESTROGEN_RESPONSE_EARLY0.300Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
BILE_ACID_METABOLISM0.200Inavolisib— uncovered
HEME_METABOLISM0.200Temsirolimus— uncovered
P53_PATHWAY0.200Idelalisib— uncovered
UV_RESPONSE_DN0.200Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.100Idelalisib— uncovered
MITOTIC_SPINDLE0.100Inavolisib— uncovered
MYOGENESIS0.100Inavolisib— uncovered
NOTCH_SIGNALING0.100Inavolisib— uncovered
TGF_BETA_SIGNALING0.100Inavolisib— uncovered